Rezidivchirurgie beim Ovarialkarzinom – wann und wie?

Holly, Jessica; Heitz, Florian; Ataseven, Beyhan und Harter, Philipp (2022): Rezidivchirurgie beim Ovarialkarzinom – wann und wie? In: Gynäkologe, Bd. 55, Nr. 3: S. 184-189

Abstract

So far, standard treatment in patients with relapsed ovarian cancer is systemic therapy;however, there is growing evidence also supporting the important role of surgery in patients with relapsed ovarian cancer. The aim of this article is to summarize the available evidence about secondary cytoreductive surgery in relapsed ovarian cancer. In three recently published studies (AGO-OVAR DESKTOP III, SOC-1 and GOG-213) the authors came to the conclusion that complete macroscopic resection is the most important factor for survival. Of the studies two showed a significant benefit in progression-free survival (PFS) and the only trial with mature overall survival data has also shown a significant benefit in survival. The challenge, however, is to select the optimal candidate. For this purpose, only the AGO score was prospectively validated. Patients with positive AGO score had a good performance status according to the Eastern Cooperative Oncology Group 0 (ECOG), a complete resection during primary surgery and no or small amounts of ascites (< 500 ml). Patients were classified as AGO score positive if all 3 factors were present. If a patient presents with a positive AGO score and a disease-free interval > 6 months, a complete resection of up to 79% can be achieved.

• Dokumententyp: Zeitschriftenartikel
• Fakultät: Medizin
• Themengebiete: 600 Technik, Medizin, angewandte Wissenschaften > 610 Medizin und Gesundheit
• ISSN: 0017-5994
• Sprache: Deutsch